Ensoma

Drug Discovery · Boston, MA · Founded 2019 · Privately Held (backing)

Operator of a biotech company intended to develop a genomic medicine in vivo approach to engineer any or all blood and immune cells to cure diseases. Ensoma is based in Boston, MA and was founded in 2019. Its last reported valuation was $280 million in May 2023. It has raised $258 million across 3 recorded rounds; the latest was a $53 million Series B1 in Sep 2025.

Last reported valuation
$280.0M
Oct 2026
Priced at
—
Total raised
$258.0M
Last round
Later Stage VC (Series B1)
Sep 2025
What is Ensoma worth?
$280.0Mlast reported valuation · Oct 2026

Ensoma's last reported valuation, May 2023. Nothing priced has surfaced since.

Free account
More of Ensoma with a free account
  • ·The complete investor list: 21 names
  • ·Watch Ensoma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Ensoma funding history

3 rounds
DateRoundRaisedPost-money
Sep 2025Later Stage VC (Series B1)$53.0M▮
May 2023Early Stage VC (Series B)$135.0M▮
Feb 2021Early Stage VC (Series A)$70.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Ensoma valuation

Ensoma's last reported valuation was $280 million in May 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Ensoma raised?

Ensoma has raised $258 million across 3 recorded rounds since 2021. The largest was a $70 million Series A in Feb 2021; the most recent was a $53 million Series B1 in Sep 2025.

Ensoma has filed 3 Form Ds with the SEC since 2021, most recently in May 2023 ($129 million sold to 22 investors).

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Mythic Therapeutics ($293 million), City Therapeutics ($285 million) and Convergent Therapeutics ($280 million).

How Ensoma's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Ensoma, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about Ensoma

What is Ensoma worth?
Ensoma is valued at $280.0M as of Oct 2026. Ensoma's last reported valuation, May 2023. Nothing priced has surfaced since.
How much has Ensoma raised?
Ensoma has raised $258.0M in total funding across 3 recorded rounds.
When did Ensoma last raise?
Ensoma last raised in Sep 2025 (Later Stage VC (Series B1)), raising $53.0M.